Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trialRoot cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under reviewPhase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H ...